Jenscare Scientific Co. Ltd. Class H (HK:9877)
:9877
Want to see HK:9877 full AI Analyst Report?
Top Page
Jenscare Scientific Co. Ltd. Class H
(9877)
Select Model
Select Model
Rating:54Neutral
Price Target:
HK$10.00
▲(5.49% Upside)
Action:N/ADate:05/05/26
The score is held back primarily by weak financial performance (large losses and ongoing cash burn despite improving revenue and strong gross margins). Technicals are moderately supportive with the stock trading above major moving averages and positive MACD, while valuation remains pressured due to negative earnings and no dividend yield provided.
Positive Factors
Revenue ramp / Commercialization
A sharp revenue ramp to about $88M in 2025 signals meaningful commercial traction for Jenscare’s transcatheter devices. Durable revenue growth off a low base indicates initial market adoption and supports scaling operating leverage as the company expands sales and clinical penetration over months.
Negative Factors
Large net losses
A cumulative net loss of roughly $264M in 2025 reflects operating expenses far outpacing current revenue. Persistent large losses undermine equity resilience and require a clear path to margin expansion and expense control before the business can sustainably convert its strong unit economics into positive net earnings.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue ramp / Commercialization
A sharp revenue ramp to about $88M in 2025 signals meaningful commercial traction for Jenscare’s transcatheter devices. Durable revenue growth off a low base indicates initial market adoption and supports scaling operating leverage as the company expands sales and clinical penetration over months.
Read all positive factors
Jenscare Scientific Co. Ltd. Class H (9877) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$5.37B
Dividend YieldN/A
Average Volume (3M)805.10K
Price to Earnings (P/E)―
Beta (1Y)0.70
Revenue GrowthN/A
EPS Growth-49.43%
CountryHK
Employees211
SectorHealthcare
Sector Strength45
IndustryMedical - Specialties
Share Statistics
EPS (TTM)-0.44
Shares Outstanding310,306,200
10 Day Avg. Volume637,060
30 Day Avg. Volume805,099
Financial Highlights & Ratios
PEG Ratio-0.26
Price to Book (P/B)4.22
Price to Sales (P/S)37.79
P/FCF Ratio-41.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.09
Revenue Forecast (FY)HK$261.02M
Jenscare Scientific Co. Ltd. Class H Business Overview & Revenue Model
Company Description
Jenscare Scientific Co., Ltd., a medical device company, engages in the research and development of invasive interventional therapies for structural heart diseases in the People's Republic of China. The company offers LuX-Valve, a transcatheter tr...
How the Company Makes Money
null...
Jenscare Scientific Co. Ltd. Class H Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
72
Positive
Cash Flow
34
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 88.24M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 66.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -210.22M | -202.04K | -429.68M | -504.82M | -501.77M |
| Net Income | -264.21M | -177.51K | -371.74M | -439.31M | -500.52M |
Balance Sheet | |||||
| Total Assets | 896.62M | 1.03B | 1.33B | 1.43B | 1.34B |
| Cash, Cash Equivalents and Short-Term Investments | 527.63M | 605.99M | 1.09B | 825.11M | 800.59M |
| Total Debt | 47.38M | 64.42M | 44.08M | 3.87M | 2.41M |
| Total Liabilities | 123.16M | 110.61M | 100.84M | 58.30M | 50.77M |
| Stockholders Equity | 789.75M | 931.76M | 1.23B | 1.37B | 1.29B |
Cash Flow | |||||
| Free Cash Flow | -80.08M | -288.81M | -300.64M | -208.03M | -157.25M |
| Operating Cash Flow | -75.00M | -217.55M | -222.44M | -158.48M | -141.89M |
| Investing Cash Flow | 5.96M | 5.59M | 358.13M | -146.58M | -475.07M |
| Financing Cash Flow | -20.61M | -110.74M | 56.44M | 188.93M | 1.08B |
Jenscare Scientific Co. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Neutral | HK$7.11B | 8.20 | 11.91% | 1.26% | 10.19% | 23.70% | |
69 Neutral | HK$8.23B | 9.35 | 11.20% | ― | 25.24% | 7.29% | |
68 Neutral | HK$8.64B | 16.88 | 4.02% | ― | 5.10% | -32.48% | |
59 Neutral | HK$3.28B | 73.09 | 2.04% | ― | 91.69% | ― | |
54 Neutral | HK$5.37B | -12.62 | -22.25% | ― | ― | -49.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$3.92B | -6.84 | -11.27% | ― | 16.35% | 9.43% |
* Healthcare Sector Average
HK:9877
Jenscare Scientific Co. Ltd. Class H
9.54
3.43
56.14%
HK:9996
Peijia Medical Ltd.
5.84
0.62
11.88%
HK:1302
LifeTech Scientific Corporation
2.00
0.45
29.03%
HK:1501
Shanghai Kindly Medical Instruments Co., Ltd. Class H
38.96
12.81
48.99%
HK:1789
AK Medical Holdings Ltd.
6.33
0.76
13.64%
HK:2235
MicroTech Medical (Hangzhou) Co., Ltd. Class H
7.80
1.43
22.45%
Jenscare Scientific Co. Ltd. Class H Corporate Events
Jenscare Scientific Calls 2025 AGM and Seeks Mandate for New Financing
Apr 28, 2026
Jenscare Scientific Co., Ltd. has convened its 2025 annual general meeting for 28 May 2026 in Ningbo, Zhejiang, where shareholders will review the board report, audited consolidated financial statements, annual report, and profit distribution plan...
Jenscare’s iJensRobo Heart Valve Robot Completes First Clinical Study in Hong Kong
Mar 30, 2026
Jenscare Scientific has announced that its iJensRobo robot-assisted transcatheter tricuspid valve replacement system has successfully completed its first clinical study in Hong Kong. In the procedure, the system was used to implant a LuX-Valve Plu...
Jenscare Scientific Posts First Commercial Revenue as Global Valve Portfolio Advances
Mar 26, 2026
Jenscare Scientific reported its first year of commercialization, generating RMB90.6 million in revenue and total income and gains of RMB107.2 million for 2025, while narrowing its adjusted non-IFRS loss to RMB162.4 million and sharply reducing op...
Jenscare Restructures Finance Leadership and Streamlines Company Secretarial Role
Mar 26, 2026
Jenscare Scientific has reshaped its senior financial leadership, appointing long-serving executive Li Yuanyuan as chief financial officer from March 26, 2026, while incumbent CFO Pan Fei steps back from that role but remains chief executive offic...
Jenscare Scientific Schedules Board Meeting to Approve 2025 Annual Results
Mar 16, 2026
Jenscare Scientific Co., Ltd. has scheduled a board meeting for March 26, 2026 to review and approve the group’s annual results for the year ended December 31, 2025 and to authorize their publication. The board will also consider recommendin...
Jenscare Wins New Zealand Approval for Key Transcatheter Heart Valves
Feb 26, 2026
Jenscare Scientific has secured registration approval in New Zealand for its Ken-Valve transcatheter aortic valve replacement system and LuX-Valve Plus transcatheter tricuspid valve replacement system. The company is now actively推进 t...
Jenscare Wins FDA Green Light for Pivotal U.S. Trial of LuX-Valve Plus
Feb 6, 2026
Jenscare Scientific has obtained unconditional investigational device exemption approval from the U.S. Food and Drug Administration for the pivotal clinical trial of LuX-Valve Plus, its independently developed transcatheter tricuspid valve replace...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.